Trial Profile
Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Gadofosveset
- Indications Congenital heart defects
- Focus Diagnostic use
- 28 Apr 2016 New trial record